🚨 New Meta-Analysis Alert! 💊🫀
Can β-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40–49%)?
📊 An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with β-blockers vs. control (HR 0.75; p=0.031) — even in the absence of clinical heart failure.
🌍 Consistent across trials and countries. Most benefit seen in patients <75 years.
📚 This could shift guidelines for a large overlooked population.
🔗 Read more in The Lancet (Aug 30, 2025)
#Cardiology #BetaBlockers #MyocardialInfarction #LVEF #EvidenceBasedMedicine #MetaAnalysis #HeartHealth 💓📉
